Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration.

Davies, Julie; Siebenhandl-Wolff, Petra; Tranquart, Francois; Jones, Paul; Evans, Paul

Davies, Julie; Siebenhandl-Wolff, Petra; Tranquart, Francois; Jones, Paul; Evans, Paul.

Affiliation

Davies J; GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK. julie.davies@ge.com.
Siebenhandl-Wolff P; GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK.
Tranquart F; GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK.
Jones P; GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK.
Evans P; GE Healthcare, Pollards Wood, Nightingales Lane, Chalfont St. Giles, UK.

Arch Toxicol ; 96(2): 403-429, 2022 02.

Article in En | MEDLINE | ID: mdl-34997254

Subject(s)

Contrast Media/administration & dosage; Gadolinium/administration & dosage; Magnetic Resonance Imaging/methods; Animals; Contrast Media/pharmacokinetics; Contrast Media/toxicity; Gadolinium/pharmacokinetics; Gadolinium/toxicity; Humans; Nephrogenic Fibrosing Dermopathy/etiology; Renal Insufficiency/complications

Key words

Gadolinium; Gadolinium-based contrast agent; Nephrogenic systemic fibrosis; Toxicity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Magnetic Resonance Imaging / Contrast Media / Gadolinium Type of study: Etiology_studies Limits: Animals / Humans Language: En Journal: Arch Toxicol Year: 2022 Type: Article Affiliation country: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google